Publications by authors named "Ana Oton"

Claim this Profile
E
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.
Ravin Ratan, Bernd Kasper, Thierry Alcindor, Patrick Schöffski, Winette T A van der Graaf, Ana B Oton

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of desmoid tumors: insights from the Desmoid Tumor Research Foundation Natural History Study, 2017-2023.
Amanda Lucas, Shengfan Zhou, Lynne Hernandez, Timothy Bell, Ana B Oton

Orphanet J Rare Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.
Elizabeth T Loggers, Rashmi Chugh, Noah Federman, Lee Hartner, Richard F Riedel, Ana B Oton

Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Desmoid Tumors: A Comprehensive Review.
Meryem Bektas, Timothy Bell, Shahnaz Khan, Brad Tumminello, Maria M Fernandez, Ana B Oton

Adv Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease and economic burden of surgery in desmoid tumors: a review.
Maria M Fernandez, Timothy Bell, Brad Tumminello, Shahnaz Khan, Shengfan Zhou, Ana B Oton

Expert Rev Pharmacoecon Outcomes Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States.
Lisa M Hess, Zhanglin Lin Cui, Xiaohong Ivy Li, Cliff Molife, Ana B Oton

Curr Med Res Opin· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Debunking Myths While Understanding Limitations.
Lisa M Hess, Katherine B Winfree, Catherine E Muehlenbein, Yajun E Zhu, Ana B Oton

Am J Public Health· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Edward B Garon, Giorgio Vittorio Scagliotti, Oliver Gautschi, Martin Reck, Michael Thomas, Ana B Oton

ESMO Open· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice.
Cliff Molife, Lisa M Hess, Zhanglin Lin Cui, Xiaohong Ivy Li, Julie Beyrer, Ana B Oton

Future Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy.
Suzanne McMullen, Lisa M Hess, Edward S Kim, Benjamin Levy, Mohamed Mohamed, Ana B Oton

Patient· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States.
Lisa M Hess, Zhanglin Lin Cui, Xiaohong Ivy Li, Ana B Oton, Scott Shortenhaus

J Med Econ· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol.
Lisa M Hess, David M Kern, Gebra Cuyun Carter, Katherine Winfree, Liya Wang, Ana B Oton

JMIR Res Protoc· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies.
Corey J Langer, Luis G Paz-Ares, Antoinette J Wozniak, Cesare Gridelli, Filippo de Marinis, Ana B Oton

Clin Lung Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and projected patient and insurer costs for the care of patients with non-small cell lung cancer in the United States through 2040.
Lisa M Hess, Zhanglin Lin Cui, Yixun Wu, Yun Fang, Paula J Gaynor, Ana B Oton

J Med Econ· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer.
Lisa M Hess, Anthony Louder, Katherine Winfree, Yajun E Zhu, Ana B Oton

J Manag Care Spec Pharm· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Mutations in Latinos From the United States and Latin America.
Ariel Lopez-Chavez, Anish Thomas, Moses O Evbuomwan, Liqiang Xi, Guinevere Chun, Ana Belen Oton

J Glob Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015.
Christian Rolfo, Christian Caglevic, Denisse Bretel, David Hong, Luis E Raez, Ana B Oton

ESMO Open· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.
Andrew J Weickhardt, Robert C Doebele, W Thomas Purcell, Paul A Bunn, Ana B Oton

Cancer· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.
Andrew J Weickhardt, Micol S Rothman, Smita Salian-Mehta, Katja Kiseljak-Vassiliades, Ana B Oton

Cancer· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.
Robert C Doebele, Xian Lu, Christopher Sumey, Delee A Maxson, Andrew J Weickhardt, Ana B Oton

Cancer· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
Andrew Weickhardt, Robert Doebele, Ana Oton, Janice Lettieri, DeLee Maxson

J Thorac Oncol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
D Ross Camidge, Scott A Kono, Xian Lu, Sonia Okuyama, Anna E Barón, Ana B Oton

J Thorac Oncol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significant downregulation of platelet gene expression in metastatic lung cancer.
David C Calverley, Tzu L Phang, Qamrul G Choudhury, Bifeng Gao, Ana B Oton

Clin Transl Sci· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Robert C Doebele, Ana B Oton, Nir Peled, D Ross Camidge, Paul A Bunn

Lung Cancer· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAGE A3 antigen-specific cancer immunotherapeutic.
Nir Peled, Ana B Oton, Fred R Hirsch, Paul Bunn

Immunotherapy· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis